A Phase 3 interventional study of AIN457 and Secukinumab Placebo in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 20th largest by enrollment, is one of 3 that started in 2021, is one of 16 in phase 3, and was the 23rd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 231 across the 26 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 26 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
31 studies in Arthritis, Psoriatic by Novartis: 3 open now, 3 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 31 studies in Arthritis, Psoriatic by Novartis, this one is the 21st largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 20th registered.
Novartis’s Arthritis, Psoriatic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 31 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the efficacy and safety of secukinumab in Chinese participants with active Psoriatic arthritis (PsA ) compared to placebo.
This study used a randomized, double-blind, placebo-controlled, parallel-group design.
A screening period running up to 10 weeks before randomization was used to assess participant eligibility followed by 52 weeks of treatment.
A follow-up visit was done 12 weeks after last study treatment administration for all participants, regardless of whether they completed the entire study as planned or discontinued prematurely.
At Baseline, the patients fulfilling the inclusion criteria were randomized to one of the following two groups.
Group 1 : Secukinumab Dose level 1 s.c. at BSL, Week 1, 2, 3, 4, 8, and 12 Group 2 : Secukinumab Placebo s.c. at BSL, Week 1, 2, 3, 4, 8, and 12.
At Week 16, participants in Group 1 and Group 2 were to be re-randomized separately in a 1:1 ratio to receive secukinumab 150 mg or secukinumab 300 mg.
The duration of the entire treatment period was 52 weeks.
The primary objective was to demonstrate the treatment effect of secukinumab in Chinese subjects with active PsA by assessing American College of Rheumatology rresponse 20 (ACR20 response) rates at Week 16.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 150 mg dose (dose level 1) of Secukinumab
Drug: AIN457
Participants received Placebo of the study drug.
Other: Secukinumab Placebo
Participants who received Placebo and switched to dose level 1 (150 mg) of secukinumab.
Drug: AIN457 · Other: Secukinumab Placebo
Participants who received Placebo and switched to dose level 2 (300 mg) of secukinumab.
Drug: AIN457 · Other: Secukinumab Placebo
Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Also known as: Secukinumab
Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
ACR20 Response at Week 16
Assessed the efficacy of secukinumab relative to placebo at week 16 using Non-responder imputation (NRI) and based on the percentage of participants achieving an ACR20 response (ACR = American College of Rheumatology). ACR20 response criteria is response ≥ 20% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (Visual Analog Scale (VAS)), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), and High-sensitivity C-reactive protein (hsCRP) or Erythrocyte sedimentation rate (ESR).
Time frame: 16 weeks
ACR50 Response at Week 16
To assess the effect of secukinumab versus placebo on the composite endpoint ACR50 response and based on the percentage of participants achieving an ACR50 response at Week 16 using NRI. ACR50 response criteria is response ≥ 50% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (VAS), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), HAQ-DI, and hsCRP or ESR.
Time frame: 16 weeks
Change From Baseline in DAS28-CRP Scores Using Mixed Model Repeated Scores (MMRM) at Week 16
To assess the effect of secukinumab versus placebo on change from BSL in DAS28-CRP. The assessment is based on the reduction in DAS28-CRP score. The DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, ESR or CRP and the Patient Global Assessment of Disease Activity. The range of DAS28 score is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.
Time frame: 16 weeks
Change From Baseline in PASDAS Scores Using MMRM at Week 16
To assess the the effect of secukinumab versus placebo on change from Baseline in PASDAS. Assessment was based on reduction in PASDAS score. PASDAS is a measure of disease activity based on Patient reported measures (excluding mental component score (MCS) of the medical outcomes survey Short Form-36 (SF-36-PCS)), skin, peripheral joint counts (Tender and Swollen joint counts), Dactylitis (LDI), Enthesitis (LEI), acute phase response (CRP) and Patient \& Physician global VAS scores. The range of PASDAS is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.
Time frame: 16 weeks
Change From Baseline in SF36-PCS Scores Using MMRM at Week 16
To assess the effect of secukinumab versus placebo on change from Baseline in SF-36 PCS. The SF-36 is a widely used and extensively studied instrument to measure HRQoL among healthy participants and participants with acute and chronic conditions. Two overall summary scores, the Physical Component Score (PCS) and the Mental Component Score (MCS) also can be computed. SF36-PCS was used in this study. The range of SF36-PCS score is 0-100. Higher score means better health status. Negative change from baseline indicates a unfavorable outcome.
Time frame: 16 weeks
Change From Baseline in HAQ-DI Scores Using MMRM at Week 16
To assess the effect of secukinumab versus placebo on change from Baseline in HAQ-DI. Assessment was based on improvement in HAQ-DI PCS scores. The HAQ-DI© is one of the most widely used measures to assess the long-term influence of chronic disease on a participant's level of functional ability and activity restriction, and calculated based on HAQ-DI questionnaire. There are 20 questions in eight categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The range of score is 0-3. Higher score means more severe disability. Negative change from baseline indicates a favorable outcome.
Time frame: 16 weeks
In the 1st 16 weeks of study, the 41 participants enrolled were randomized to 2 groups: 1 group received secukinumab 150 mg \& the other received placebo. At week 16, the participants were re-randomized within each group for a total of 4 groups. Within the secukinumab group, 1 group continued to receive secukinumab 150 mg while the other half received secukinumab 300 mg. In the Placebo group, 1 group switched to secukinumab 150 mg while the other half switched to secukinumab 300 mg.
| Milestone | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) | Secukinumab 150 mg to Secukinumab 150 mg (2nd Randomization) | Secukinumab 150 mg to Secukinumab 300 mg (2nd Randomization) | Placebo to Secukinumab 150 mg (2nd Randomization) | Placebo to Secukinumab 300 mg (2nd Randomization) |
|---|---|---|---|---|---|---|
| Started | 20 | 21 | 0 | 0 | 0 | 0 |
| Completed | 20 | 21 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) | Secukinumab 150 mg to Secukinumab 150 mg (2nd Randomization) | Secukinumab 150 mg to Secukinumab 300 mg (2nd Randomization) | Placebo to Secukinumab 150 mg (2nd Randomization) | Placebo to Secukinumab 300 mg (2nd Randomization) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 10 | 10 | 10 | 11 |
| Discont. from treatment before week 52 | 0 | 0 | 0 | 0 | 1 | 0 |
| Completed study treatment | 0 | 0 | 10 | 10 | 9 | 11 |
| Completed | 0 | 0 | 8 | 10 | 10 | 11 |
| Not completed | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Participant decision | 0 | 0 | 2 | 0 | 0 | 0 |
Assessed the efficacy of secukinumab relative to placebo at week 16 using Non-responder imputation (NRI) and based on the percentage of participants achieving an ACR20 response (ACR = American College of Rheumatology). ACR20 response criteria is response ≥ 20% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (Visual Analog Scale (VAS)), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), and High-sensitivity C-reactive protein (hsCRP) or Erythrocyte sedimentation rate (ESR).
| Participants | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) |
|---|---|---|
| ACR20 Response at Week 16 | 14 | 6 |
To assess the effect of secukinumab versus placebo on the composite endpoint ACR50 response and based on the percentage of participants achieving an ACR50 response at Week 16 using NRI. ACR50 response criteria is response ≥ 50% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (VAS), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), HAQ-DI, and hsCRP or ESR.
| Participants | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) |
|---|---|---|
| ACR50 Response at Week 16 | 3 | 1 |
To assess the effect of secukinumab versus placebo on change from BSL in DAS28-CRP. The assessment is based on the reduction in DAS28-CRP score. The DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, ESR or CRP and the Patient Global Assessment of Disease Activity. The range of DAS28 score is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.
| scores on a scale | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) |
|---|---|---|
| Change From Baseline in DAS28-CRP Scores Using Mixed Model Repeated Scores (MMRM) at Week 16 | -1.47 ± 0.206 | -0.37 ± 0.200 |
To assess the the effect of secukinumab versus placebo on change from Baseline in PASDAS. Assessment was based on reduction in PASDAS score. PASDAS is a measure of disease activity based on Patient reported measures (excluding mental component score (MCS) of the medical outcomes survey Short Form-36 (SF-36-PCS)), skin, peripheral joint counts (Tender and Swollen joint counts), Dactylitis (LDI), Enthesitis (LEI), acute phase response (CRP) and Patient \& Physician global VAS scores. The range of PASDAS is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.
| scores on a scale | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) |
|---|---|---|
| Change From Baseline in PASDAS Scores Using MMRM at Week 16 | -2.20 ± 0.245 | -0.55 ± 0.237 |
To assess the effect of secukinumab versus placebo on change from Baseline in SF-36 PCS. The SF-36 is a widely used and extensively studied instrument to measure HRQoL among healthy participants and participants with acute and chronic conditions. Two overall summary scores, the Physical Component Score (PCS) and the Mental Component Score (MCS) also can be computed. SF36-PCS was used in this study. The range of SF36-PCS score is 0-100. Higher score means better health status. Negative change from baseline indicates a unfavorable outcome.
| scores on a scale | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) |
|---|---|---|
| Change From Baseline in SF36-PCS Scores Using MMRM at Week 16 | 4.28 ± 1.154 | 0.08 ± 1.113 |
To assess the effect of secukinumab versus placebo on change from Baseline in HAQ-DI. Assessment was based on improvement in HAQ-DI PCS scores. The HAQ-DI© is one of the most widely used measures to assess the long-term influence of chronic disease on a participant's level of functional ability and activity restriction, and calculated based on HAQ-DI questionnaire. There are 20 questions in eight categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The range of score is 0-3. Higher score means more severe disability. Negative change from baseline indicates a favorable outcome.
| scores on a scale | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) |
|---|---|---|
| Change From Baseline in HAQ-DI Scores Using MMRM at Week 16 | -0.31 ± 0.065 | 0.09 ± 0.063 |
Collected over Adverse events were collected from first dose of study treatment to 30 days after last dose of study medication (on-treatment), up to approx. 52 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any AIN457 150 mg | 0/30 (0%) | 0/30 (0%) | 27/30 (90%) |
| Any AIN457 300 mg | 0/21 (0%) | 1/21 (4.8%) | 16/21 (76.2%) |
| Any AIN457 | 0/41 (0%) | 1/41 (2.4%) | 37/41 (90.2%) |
| Placebo | 0/21 (0%) | 0/21 (0%) | 16/21 (76.2%) |
| Event | Any AIN457 150 mg | Any AIN457 300 mg | Any AIN457 | Placebo |
|---|---|---|---|---|
| CataractEye disorders | 0/30 | 1/21 | 1/41 | 0/21 |
| Epiretinal membraneEye disorders | 0/30 | 1/21 | 1/41 | 0/21 |
| Event | Any AIN457 150 mg | Any AIN457 300 mg | Any AIN457 | Placebo |
|---|---|---|---|---|
| HyperlipidaemiaMetabolism and nutrition disorders | 6/30 | 3/21 | 9/41 | 8/21 |
| COVID-19Infections and infestations | 4/30 | 5/21 | 9/41 | 0/21 |
| HyperuricaemiaMetabolism and nutrition disorders | 5/30 | 4/21 | 9/41 | 2/21 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 5/30 | 0/21 | 5/41 | 0/21 |
| HypertensionVascular disorders | 4/30 | 0/21 | 4/41 | 1/21 |
| Hepatic function abnormalHepatobiliary disorders | 3/30 | 2/21 | 5/41 | 0/21 |
| Suspected COVID-19Infections and infestations | 3/30 | 2/21 | 5/41 | 0/21 |
| Weight increasedInvestigations | 3/30 | 0/21 | 3/41 | 1/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/30 | 2/21 | 4/41 | 0/21 |
| Alanine aminotransferase increasedInvestigations | 0/30 | 0/21 | 0/41 | 2/21 |
Randomized set: All participants who were randomized.
| Age, Continuous(years) | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) | Total |
|---|---|---|---|
| Mean | 42.4 ± 9.70 | 45.7 ± 10.46 | 44.0 ± 10.11 |
| Sex: Female, Male(Participants) | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) | Total |
|---|---|---|---|
| Female | 13 | 5 | 18 |
| Male | 7 | 16 | 23 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 150 mg (Group 1) | Placebo of Study Drug (Group 2) | Total |
|---|---|---|---|
| Chinese | 20 | 21 | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jun 2021 to primary completion in Jun 2022, 11 months.
Results were first posted in Jul 2024, 2 years 1 month after primary completion. A results delay was requested in Apr 2023.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 11 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab